Cara Therapeutics Profit Margin 2012-2021 | CARA

Current and historical gross margin, operating margin and net profit margin for Cara Therapeutics (CARA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Cara Therapeutics net profit margin as of June 30, 2021 is 10.88%.
Cara Therapeutics Annual Profit Margins
Cara Therapeutics Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.643B $0.135B
Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43